Biogen Inc.
A biopharmaceutical company focused on the brain and nervous system, Biogen makes treatments for multiple sclerosis, spinal muscular atrophy, ALS, and Alzheimer's — with brands like TYSABRI, SPINRAZA, and the Alzheimer's drug LEQEMBI it co-markets with Eisai. It was founded in 1978 in Geneva by academic scientists (including two future Nobel laureates) and later moved to Cambridge, Massachusetts, where it remains. Its name is a mash-up of "Biotechnology Geneva," and its roots stretch back to the dawn of the biotech industry.
| Holder | Schedule | % of class | Shares | Filed |
|---|---|---|---|---|
| FMR LLC | 13G/APassive | 12.4% | 18.29M | Aug 6, 2026 |
| Abigail P. Johnson | 13G/APassive | 12.4% | 18.29M | Aug 6, 2026 |
| Vanguard Capital Management | 13GPassive | 7.48% | 10.99M | Apr 29, 2026 |
| The Vanguard Group | 13G/APassive | 0% | 0 | Mar 26, 2026 |
| PRIMECAP MANAGEMENT CO/CA/ | 13G/APassive | 10.2% | 14.95M | Nov 13, 2025 |
| STATE STREET CORPORATION | 13GPassive | 5% | 7.32M | Nov 10, 2025 |
| BlackRock, Inc. | 13G/APassive | 8.5% | 12.51M | Apr 17, 2025 |